Back to resultsChemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
Primary Purpose
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
carboplatin
cisplatin
conventional surgery
neoadjuvant therapy
Sponsored by
About this trial
This is an interventional treatment trial for Fallopian Tube Cancer focused on measuring stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven stage IIIC or IV ovarian epithelial carcinoma, peritoneal carcinoma, or fallopian tube carcinoma If biopsy is not available, evidence of adenocarcinoma by fine needle aspiration allowed if all of the following are true: Presence of pelvic ovarian mass Omental cake or other metastasis larger than 2 cm in the upper abdomen and/or regional lymph node metastasis CA 125/carcinoembryonic antigen ratio greater than 25 (if ratio less than 25, barium enema or colonoscopy AND gastroscopy or radiological examination of the stomach must be negative for primary tumor) Normal mammography (if CA 125/carcinoembryonic antigen ratio less than 25) Tumor greater than 2 cm, excluding ovaries, on laparoscopy or CT scan No brain or leptomeningeal metastases PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm^3 Platelet count greater than 100,000/mm^3 Hepatic: Bilirubin less than 1.25 times upper limit of normal (ULN) Renal: Creatinine less than 1.25 times ULN Other: No other serious disabling diseases contraindicating primary cytoreductive surgery or primary platin-based chemotherapy No other prior primary malignancies except carcinoma in situ of the cervix or basal cell carcinoma of the skin No psychological, familial, sociological, or geographical condition potentially preventing protocol compliance or follow-up PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery No other prior procedures except diagnostic biopsy by laparotomy or laparoscopy
Sites / Locations
- Hospital de Clinicas "Jose De San Martin"
- Shaare Zedek Medical Center
- Karl-Franzens-University Graz
- Innsbruck Universitaetsklinik
- Allgemeines Krankenhaus - Universitatskliniken
- Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital
- Academisch Ziekenhuis der Vrije Universiteit Brussel
- Universitair Ziekenhuis Antwerpen
- Cazk Groeninghe - Campus Maria's Voorzienigheid
- U.Z. Gasthuisberg
- Tom Baker Cancer Centre - Calgary
- BCCA - Fraser Valley Cancer Centre
- British Columbia Cancer Agency - Vancouver Cancer Centre
- CancerCare Manitoba
- Saint John Regional Hospital
- Doctor H. Bliss Murphy Cancer Centre
- Nova Scotia Cancer Centre
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
- CHUS-Hopital Fleurimont
- Hopital Charles Lemoyne
- McGill Cancer Centre at McGill University
- Hopital Notre-Dame du CHUM
- Herlev Hospital - University Hospital of Copenhagen
- Institut Bergonie
- Centre Oscar Lambret
- Centre Hospitalier Regional et Universitaire de Lille
- Institut Claudius Regaud
- Martin Luther Universitaet
- Coombe Women's Hospital
- St. James's Hospital
- Spedali Civili di Brescia
- Mirano General Hospital
- Libero Istituto Universitario Campus Bio-Medico
- Azienda Sanitaria Ospedaliera Ordine Mauriziano
- Clinica Universitaria
- Vrije Universiteit Medisch Centrum
- Akademisch Ziekenhuis Vrije Universiteit - Medisch Centrum
- Onze Lieve Vrouwe Gasthuis
- Academisch Medisch Centrum at University of Amsterdam
- Leiden University Medical Center
- Universitair Medisch Centrum St. Radboud - Nijmegen
- Daniel Den Hoed Cancer Center at Erasmus Medical Center
- Erasmus MC - Sophia Children's Hospital
- Haukeland Hospital - University of Bergen
- Norwegian Radium Hospital
- Hospitais da Universidade de Coimbra (HUC)
- Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.
- Institut d'Oncologia Corachan
- Hospital Universitario San Carlos
- Hospital Universitario 12 de Octubre
- Hospital Universitario Central de Asturias
- Lund University Hospital
- Karolinska University Hospital - Huddinge
- Umea Universitet
- Uppsala University Hospital
- Royal United Hospital
- Cheltenham General Hospital
- University College of London Hospitals
- Clatterbridge Centre for Oncology NHS Trust
- James Cook University Hospital
- Mount Vernon Cancer Centre at Mount Vernon Hospital
- Nottingham City Hospital NHS Trust
- Staffordshire General Hospital
- Western Infirmary
- Queen Elizabeth The Queen Mother Hospital
Outcomes
Primary Outcome Measures
Overall survival as measured by Kaplan Meier every 3 months for 2 years, every 6 months for 3 years, and then annually
Secondary Outcome Measures
Progression-free survival as measured by Kaplan Meier and RECIST every 3 months for 2 years, every 6 months for 3 years, and then annually
Health-related quality of life as measured by Quality of Life Questionnaire-C30 after courses 1, 3 and 6, then at 6 and 12 months
Toxicity as measured by NCIC Common Toxicity Criteria v2.0 within 4 weeks of surgery
Full Information
NCT ID
NCT00003636
First Posted
November 1, 1999
Last Updated
August 4, 2015
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
1. Study Identification
Unique Protocol Identification Number
NCT00003636
Brief Title
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
Official Title
A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
September 1998 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
4. Oversight
5. Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after surgery with or without additional surgery in treating patients with stage III or stage IV ovarian cancer, peritoneal cancer, or fallopian tube cancer.
Detailed Description
OBJECTIVES:
Compare the overall survival and progression-free survival in patients with stage IIIC or IV ovarian epithelial, peritoneal, or fallopian tube carcinoma treated with neoadjuvant chemotherapy followed by interval debulking surgery versus upfront cytoreductive surgery followed by chemotherapy with or without interval debulking surgery.
Compare the quality of life of patients treated with these regimens.
Compare the different treatment complications in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, method of biopsy, stage, largest tumor size before surgery, and intent to also randomize on EORTC-55012. Patients are randomized to one of two treatment arms.
Arm I: Patients undergo upfront maximal cytoreductive surgery followed by cisplatin or carboplatin IV every 3 weeks for 3 courses. Patients with non-optimal primary debulking may undergo interval debulking surgery at the physician's discretion. All patients then receive an additional 3 courses of the same regimen of chemotherapy.
Arm II: Patients receive chemotherapy as in arm I. Patients with stable or responding disease undergo interval debulking surgery followed by an additional 3 courses of the same regimen of chemotherapy.
Second-look surgery is allowed for both arms if clinically indicated.
Quality of life (QOL) is assessed prior to treatment, after the third and sixth course of chemotherapy, and at 6 and 12 months after study. Patients who are also randomized on EORTC-55012 follow the QOL assessment schedule for EORTC-55012 only.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 704 patients will be accrued for this study within 4 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Keywords
stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Allocation
Randomized
Enrollment
704 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
carboplatin
Intervention Type
Drug
Intervention Name(s)
cisplatin
Intervention Type
Procedure
Intervention Name(s)
conventional surgery
Intervention Type
Procedure
Intervention Name(s)
neoadjuvant therapy
Primary Outcome Measure Information:
Title
Overall survival as measured by Kaplan Meier every 3 months for 2 years, every 6 months for 3 years, and then annually
Secondary Outcome Measure Information:
Title
Progression-free survival as measured by Kaplan Meier and RECIST every 3 months for 2 years, every 6 months for 3 years, and then annually
Title
Health-related quality of life as measured by Quality of Life Questionnaire-C30 after courses 1, 3 and 6, then at 6 and 12 months
Title
Toxicity as measured by NCIC Common Toxicity Criteria v2.0 within 4 weeks of surgery
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically proven stage IIIC or IV ovarian epithelial carcinoma, peritoneal carcinoma, or fallopian tube carcinoma
If biopsy is not available, evidence of adenocarcinoma by fine needle aspiration allowed if all of the following are true:
Presence of pelvic ovarian mass
Omental cake or other metastasis larger than 2 cm in the upper abdomen and/or regional lymph node metastasis
CA 125/carcinoembryonic antigen ratio greater than 25 (if ratio less than 25, barium enema or colonoscopy AND gastroscopy or radiological examination of the stomach must be negative for primary tumor)
Normal mammography (if CA 125/carcinoembryonic antigen ratio less than 25)
Tumor greater than 2 cm, excluding ovaries, on laparoscopy or CT scan
No brain or leptomeningeal metastases
PATIENT CHARACTERISTICS:
Age:
Not specified
Performance status:
WHO 0-2
Life expectancy:
Not specified
Hematopoietic:
WBC greater than 3,000/mm^3
Platelet count greater than 100,000/mm^3
Hepatic:
Bilirubin less than 1.25 times upper limit of normal (ULN)
Renal:
Creatinine less than 1.25 times ULN
Other:
No other serious disabling diseases contraindicating primary cytoreductive surgery or primary platin-based chemotherapy
No other prior primary malignancies except carcinoma in situ of the cervix or basal cell carcinoma of the skin
No psychological, familial, sociological, or geographical condition potentially preventing protocol compliance or follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
Not specified
Endocrine therapy
Not specified
Radiotherapy
Not specified
Surgery
No other prior procedures except diagnostic biopsy by laparotomy or laparoscopy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ignace B. Vergote, MD, PhD
Organizational Affiliation
U.Z. Gasthuisberg, Leuven
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital de Clinicas "Jose De San Martin"
City
Buenos Aires
ZIP/Postal Code
1120
Country
Argentina
Facility Name
Shaare Zedek Medical Center
City
Buenos Aires
ZIP/Postal Code
1120
Country
Argentina
Facility Name
Karl-Franzens-University Graz
City
Graz
ZIP/Postal Code
A-8010
Country
Austria
Facility Name
Innsbruck Universitaetsklinik
City
Innsbruck
ZIP/Postal Code
A-6020
Country
Austria
Facility Name
Allgemeines Krankenhaus - Universitatskliniken
City
Vienna
ZIP/Postal Code
A-1090
Country
Austria
Facility Name
Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital
City
Vienna
ZIP/Postal Code
A-1100
Country
Austria
Facility Name
Academisch Ziekenhuis der Vrije Universiteit Brussel
City
Brussels
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
B-2650
Country
Belgium
Facility Name
Cazk Groeninghe - Campus Maria's Voorzienigheid
City
Kortrijk
ZIP/Postal Code
B-8500
Country
Belgium
Facility Name
U.Z. Gasthuisberg
City
Leuven
ZIP/Postal Code
B-3000
Country
Belgium
Facility Name
Tom Baker Cancer Centre - Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N2
Country
Canada
Facility Name
BCCA - Fraser Valley Cancer Centre
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V 1Z2
Country
Canada
Facility Name
British Columbia Cancer Agency - Vancouver Cancer Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
Facility Name
CancerCare Manitoba
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3E 0V9
Country
Canada
Facility Name
Saint John Regional Hospital
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
Doctor H. Bliss Murphy Cancer Centre
City
St. Johns
State/Province
Newfoundland and Labrador
ZIP/Postal Code
A1B 3V6
Country
Canada
Facility Name
Nova Scotia Cancer Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1V7
Country
Canada
Facility Name
Cancer Centre of Southeastern Ontario at Kingston General Hospital
City
Kingston
State/Province
Ontario
ZIP/Postal Code
K7L 5P9
Country
Canada
Facility Name
CHUS-Hopital Fleurimont
City
Fleurimont
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Facility Name
Hopital Charles Lemoyne
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2H1
Country
Canada
Facility Name
McGill Cancer Centre at McGill University
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2W 1S6
Country
Canada
Facility Name
Hopital Notre-Dame du CHUM
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4L 2M1
Country
Canada
Facility Name
Herlev Hospital - University Hospital of Copenhagen
City
Copenhagen
ZIP/Postal Code
DK-2730
Country
Denmark
Facility Name
Institut Bergonie
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59020
Country
France
Facility Name
Centre Hospitalier Regional et Universitaire de Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Institut Claudius Regaud
City
Toulouse
ZIP/Postal Code
31052
Country
France
Facility Name
Martin Luther Universitaet
City
Halle
ZIP/Postal Code
D-06112
Country
Germany
Facility Name
Coombe Women's Hospital
City
Dublin
ZIP/Postal Code
8
Country
Ireland
Facility Name
St. James's Hospital
City
Dublin
ZIP/Postal Code
8
Country
Ireland
Facility Name
Spedali Civili di Brescia
City
Brescia
ZIP/Postal Code
25124
Country
Italy
Facility Name
Mirano General Hospital
City
Mirano-Venice
ZIP/Postal Code
30035
Country
Italy
Facility Name
Libero Istituto Universitario Campus Bio-Medico
City
Rome
ZIP/Postal Code
00155
Country
Italy
Facility Name
Azienda Sanitaria Ospedaliera Ordine Mauriziano
City
Torino
ZIP/Postal Code
10128
Country
Italy
Facility Name
Clinica Universitaria
City
Turin
ZIP/Postal Code
10138
Country
Italy
Facility Name
Vrije Universiteit Medisch Centrum
City
Amsterdam
ZIP/Postal Code
1007 MB
Country
Netherlands
Facility Name
Akademisch Ziekenhuis Vrije Universiteit - Medisch Centrum
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Onze Lieve Vrouwe Gasthuis
City
Amsterdam
ZIP/Postal Code
1091 HA
Country
Netherlands
Facility Name
Academisch Medisch Centrum at University of Amsterdam
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
Leiden University Medical Center
City
Leiden
ZIP/Postal Code
2300 CA
Country
Netherlands
Facility Name
Universitair Medisch Centrum St. Radboud - Nijmegen
City
Nijmegen
ZIP/Postal Code
NL-6500 HB
Country
Netherlands
Facility Name
Daniel Den Hoed Cancer Center at Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3008 AE
Country
Netherlands
Facility Name
Erasmus MC - Sophia Children's Hospital
City
Rotterdam
ZIP/Postal Code
3015 GJ
Country
Netherlands
Facility Name
Haukeland Hospital - University of Bergen
City
Bergen
ZIP/Postal Code
N-5021
Country
Norway
Facility Name
Norwegian Radium Hospital
City
Oslo
ZIP/Postal Code
N-0310
Country
Norway
Facility Name
Hospitais da Universidade de Coimbra (HUC)
City
Coimbra
ZIP/Postal Code
3049
Country
Portugal
Facility Name
Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.
City
Lisbon
ZIP/Postal Code
1099-023 Codex
Country
Portugal
Facility Name
Institut d'Oncologia Corachan
City
Barcelona
ZIP/Postal Code
08.017
Country
Spain
Facility Name
Hospital Universitario San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital Universitario Central de Asturias
City
Oviedo
ZIP/Postal Code
33006
Country
Spain
Facility Name
Lund University Hospital
City
Lund
ZIP/Postal Code
SE-22185
Country
Sweden
Facility Name
Karolinska University Hospital - Huddinge
City
Stockholm
ZIP/Postal Code
S - 141 86
Country
Sweden
Facility Name
Umea Universitet
City
Umea
ZIP/Postal Code
SE-901 87
Country
Sweden
Facility Name
Uppsala University Hospital
City
Uppsala
ZIP/Postal Code
SE-75185
Country
Sweden
Facility Name
Royal United Hospital
City
Bath
State/Province
England
ZIP/Postal Code
BA1 3NG
Country
United Kingdom
Facility Name
Cheltenham General Hospital
City
Cheltenham
State/Province
England
ZIP/Postal Code
GL53 7AN
Country
United Kingdom
Facility Name
University College of London Hospitals
City
London
State/Province
England
ZIP/Postal Code
WIT 3AA
Country
United Kingdom
Facility Name
Clatterbridge Centre for Oncology NHS Trust
City
Merseyside
State/Province
England
ZIP/Postal Code
CH63 4JY
Country
United Kingdom
Facility Name
James Cook University Hospital
City
Middlesbrough
State/Province
England
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Facility Name
Mount Vernon Cancer Centre at Mount Vernon Hospital
City
Northwood
State/Province
England
ZIP/Postal Code
HA6 2RN
Country
United Kingdom
Facility Name
Nottingham City Hospital NHS Trust
City
Nottingham
State/Province
England
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Staffordshire General Hospital
City
Stafford
State/Province
England
ZIP/Postal Code
ST16 3SA
Country
United Kingdom
Facility Name
Western Infirmary
City
Glasgow
State/Province
Scotland
ZIP/Postal Code
G11 6NT
Country
United Kingdom
Facility Name
Queen Elizabeth The Queen Mother Hospital
City
Margate
ZIP/Postal Code
CT9 4AN
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
21917306
Citation
Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.
Results Reference
background
PubMed Identifier
20850296
Citation
Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer. 2011 Jan;47(1):57-64. doi: 10.1016/j.ejca.2010.08.008. Epub 2010 Sep 16.
Results Reference
result
PubMed Identifier
20818904
Citation
Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
Results Reference
result
Citation
Fruehauf JP, Yu I, Parker R: In vitro drug response and biomarker profiles for ovarian cancer specimens obtained at initial debulking or after neoadjuvant chemotherapy (EORTC 55971). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-2177, 2002.
Results Reference
result
PubMed Identifier
29324537
Citation
Tajik P, van de Vrie R, Zafarmand MH, Coens C, Buist MR, Vergote I, Bossuyt PMM, Kenter GG. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy. Int J Gynecol Cancer. 2018 Mar;28(3):453-458. doi: 10.1097/IGC.0000000000001186.
Results Reference
derived
PubMed Identifier
25964591
Citation
Vizzielli G, Fanfani F, Chiantera V, Tortorella L, Lucidi A, Petrillo M, Costantini B, Scambia G, Fagotti A. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy? Anticancer Res. 2015 May;35(5):3027-32.
Results Reference
derived
PubMed Identifier
23850170
Citation
van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW, Buist MR, Bossuyt PM. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013 Oct;49(15):3191-201. doi: 10.1016/j.ejca.2013.06.013. Epub 2013 Jul 11.
Results Reference
derived
Learn more about this trial
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
We'll reach out to this number within 24 hrs